MedTrace Logo

Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults

NCT01389479 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2017-06-08

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety, tolerance and immunogenicity of Fluviral™ in healthy adults aged 18-64 years.

Conditions

Interventions

BIOLOGICAL

Fluviral™

Intramuscular, single dose

BIOLOGICAL

Fluzone®

Intramuscular, single dose

Sponsors & Collaborators

  • ID Biomedical Corporation, Quebec

    collaborator INDUSTRY

  • GlaxoSmithKline

    lead INDUSTRY

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2005-05-31
Completion
2005-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01389479 on ClinicalTrials.gov